The Bird Flu: A New Emerging Pandemic Threat And Its Pharmacological Intervention
Abstract
Bird flu is an infection caused by avian influenza viruses, which are of different types A, B and C. Type A avian influenza viruses
are the most frequently associated with avian influenza epidemics and pandemics. There are 16 hemagglutinin (H1 to H16) and
9 neuraminidase types (N1 to N9) identified till date. A peculiar characteristic of influenza A viruses is their propensity for
genetic change by two main processes: antigenic drift (small, gradual changes) and antigenic shift (abrupt, major change
producing a novel influenza A virus subtype).
There are various modes of transmission of human influenza including inhalation, direct or indirect (fomite) contact etc., can
have manifestations ranging from mild to severe or fatal disease, depend on the viral subtype causing the disease. Avian
influenza A (H5N1) results in high death rate amongst infants and young children.
The first outbreak of human infection by avian influenza viruses (H5N1) was observed in 1997 in Hong Kong. Since then a large
number of outbreaks have been reported in different parts of the world. In fact, the spread of avian influenza H5N1 in various
species including humans has lead to a current pandemic threat.
Human avian influenza infections in persons at high risk of exposure can be prevented by adopting a series of protective
measures, anti-viral vaccination and health monitoring. Drugs currently available for the treatment or prophylaxis of influenza
infections include the adamantanes (amantadine and rimantadine) and the newer class of neuraminidase inhibitors (zanamivir,
oseltamivir and peramivir). However, vaccines are considered the first line of defense for reducing the excess morbidity and
mortality that invariably accompany pandemics and a number of clinical trials are under way to test them.
are the most frequently associated with avian influenza epidemics and pandemics. There are 16 hemagglutinin (H1 to H16) and
9 neuraminidase types (N1 to N9) identified till date. A peculiar characteristic of influenza A viruses is their propensity for
genetic change by two main processes: antigenic drift (small, gradual changes) and antigenic shift (abrupt, major change
producing a novel influenza A virus subtype).
There are various modes of transmission of human influenza including inhalation, direct or indirect (fomite) contact etc., can
have manifestations ranging from mild to severe or fatal disease, depend on the viral subtype causing the disease. Avian
influenza A (H5N1) results in high death rate amongst infants and young children.
The first outbreak of human infection by avian influenza viruses (H5N1) was observed in 1997 in Hong Kong. Since then a large
number of outbreaks have been reported in different parts of the world. In fact, the spread of avian influenza H5N1 in various
species including humans has lead to a current pandemic threat.
Human avian influenza infections in persons at high risk of exposure can be prevented by adopting a series of protective
measures, anti-viral vaccination and health monitoring. Drugs currently available for the treatment or prophylaxis of influenza
infections include the adamantanes (amantadine and rimantadine) and the newer class of neuraminidase inhibitors (zanamivir,
oseltamivir and peramivir). However, vaccines are considered the first line of defense for reducing the excess morbidity and
mortality that invariably accompany pandemics and a number of clinical trials are under way to test them.
Mittal, N., & Medhi, B. (2007). The Bird Flu: A New Emerging Pandemic Threat And Its Pharmacological Intervention. International Journal of Health Sciences, 1(2). Retrieved from https://pub.qu.edu.sa/index.php/journal/article/view/101
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Copyright and license info is not available